Commonwealth Equity Services LLC trimmed its position in shares of Invesco Dynamic Biotechnology & Genome ETF (NYSEARCA:PBE – Get Rating) by 1.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,662 shares of the company's stock after selling 173 shares during the period. Commonwealth Equity Services LLC owned approximately 0.25% of Invesco Dynamic Biotechnology & Genome ETF worth $557,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Royal Bank of Canada grew its stake in shares of Invesco Dynamic Biotechnology & Genome ETF by 8.8% in the 1st quarter. Royal Bank of Canada now owns 73,653 shares of the company's stock valued at $4,568,000 after purchasing an additional 5,942 shares during the period. Artemis Wealth Advisors LLC bought a new stake in shares of Invesco Dynamic Biotechnology & Genome ETF in the 1st quarter valued at approximately $4,144,000. Cetera Advisor Networks LLC grew its stake in shares of Invesco Dynamic Biotechnology & Genome ETF by 23.3% in the 1st quarter. Cetera Advisor Networks LLC now owns 26,604 shares of the company's stock valued at $1,650,000 after purchasing an additional 5,019 shares during the period. YHB Investment Advisors Inc. grew its stake in shares of Invesco Dynamic Biotechnology & Genome ETF by 8.3% in the 1st quarter. YHB Investment Advisors Inc. now owns 23,309 shares of the company's stock valued at $1,446,000 after purchasing an additional 1,784 shares during the period. Finally, First Republic Investment Management Inc. grew its stake in shares of Invesco Dynamic Biotechnology & Genome ETF by 59.2% in the 1st quarter. First Republic Investment Management Inc. now owns 12,402 shares of the company's stock valued at $769,000 after purchasing an additional 4,612 shares during the period.
Get Invesco Dynamic Biotechnology & Genome ETF alerts:Invesco Dynamic Biotechnology & Genome ETF Trading Up 2.1 %
PBE stock opened at $60.67 on Friday. Invesco Dynamic Biotechnology & Genome ETF has a 1-year low of $51.39 and a 1-year high of $77.36. The business's 50 day moving average is $61.02 and its 200-day moving average is $59.61.
Invesco Dynamic Biotechnology & Genome ETF Company Profile
(Get Rating)PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.
Featured Articles
- Get a free copy of the StockNews.com research report on Invesco Dynamic Biotechnology & Genome ETF (PBE)
- Should Investors Raise a Glass to Boston Beer Company?
- MarketBeat: Week in Review 10/17-10/21
- Snap Stock Falls As User Growth Slows To Single-Digits
- American Express Beats Earnings & Revenue Views, Raises Guidance
- The Institutions Spin Whirlpool Into Bargain Basement Territory
Want to see what other hedge funds are holding PBE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Invesco Dynamic Biotechnology & Genome ETF (NYSEARCA:PBE – Get Rating).
Receive News & Ratings for Invesco Dynamic Biotechnology & Genome ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invesco Dynamic Biotechnology & Genome ETF and related companies with MarketBeat.com's FREE daily email newsletter.